Opioid Brain Injury
Chronic musculoskeletal pain — persistent low back pain, osteoarthritis, widespread myofascial pain — is among the most common and most consequential conditions I treat. For decades, opioids were a default component of the management strategy for these patients, normalized by prescribing culture, patient expectation, and a genuine lack of alternatives that were being offered consistently. That era is ending, and not because of regulatory pressure alone — but because the evidence has become impossible to rationalize away. I do not prescribe opioids for chronic musculoskeletal or orthopedic conditions. That position is not ideological — it is the direct conclusion of what the medical literature tells us about what these medications do, and do not do, for this patient population.
THE BASICS
Why Opioids Are Not the Answer for Chronic Musculoskeletal Pain
Opioids were developed for acute pain, cancer pain, and end-of-life comfort — contexts where short-term analgesia is the primary goal and long-term biological consequences are secondary considerations. Chronic non-cancer musculoskeletal pain is a fundamentally different problem, and the evidence that opioids address it effectively is remarkably thin. Studies consistently show only modest improvements in pain and function with opioid therapy, improvements that are frequently outweighed by side effects and that do not persist over time. After months or years of use, patients on long-term opioid therapy often report no greater pain relief than patients managed with non-opioid alternatives — while carrying a substantially higher burden of adverse effects, dependence, and physiological harm. Tolerance develops with chronic use, requiring dose escalation that increases risk without producing proportional benefit.
The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain found that a long-term randomized trial of stepped therapy for chronic musculoskeletal pain showed no meaningful difference in function and actually higher pain intensity in patients who began with opioid therapy compared to those who started with nonopioid therapy. That is not a fringe position — it is the current consensus of the leading public health and clinical authorities in this space. Existing clinical practice guidelines from the American Academy of Orthopaedic Surgeons do not include opioids for chronic musculoskeletal conditions due to limited evidence of efficacy, and while opioids may offer some short-term benefit for back pain, their long-term effectiveness is complicated by tolerance and opioid-induced hyperalgesia.
This does not mean opioids have no role in medicine. For severe traumatic injuries, invasive surgeries typically associated with moderate to severe postoperative pain, and other acute severe pain situations, opioids remain clinically appropriate — and nonopioid therapies are recognized as at least as effective as opioids for many common acute pain conditions including low back pain, neck pain, and musculoskeletal injuries such as sprains, strains, tendonitis, and bursitis. The critical distinction is between appropriately supervised short-term acute use and the long-term, open-ended prescribing that has produced an irreversible public health crisis.
CLINICAL EVIDENCE
Two Mechanisms of Harm That Deserve More Attention
Beyond the well-publicized risks of dependence, overdose, and hormonal dysregulation, two specific biological consequences of chronic opioid use are insufficiently discussed with patients and deserve direct attention in the clinical conversation.
The first is structural brain injury. Neuroimaging studies have documented gray matter atrophy in the prefrontal cortex — the region governing decision-making, impulse control, and executive function — as well as volume reduction in the amygdala and anterior cingulate cortex, areas central to pain modulation and emotional regulation. These changes have been observed even in younger users and correlate with duration of exposure and cumulative dose. Some of these alterations appear to be partially irreversible. I have described this constellation of neurological damage as Opioid Brain Injury — a term intended to capture what is medically characterized as toxic leukoencephalopathy resulting from opioid exposure, encompassing the white matter injury and structural changes that chronic opioid use produces in the central nervous system. Upadhyay et al. in the Journal of Neuroscience documented these alterations directly in prescription opioid-dependent patients, finding persistent and potentially irreversible changes in brain structure and functional connectivity. The clinical consequences — cognitive dysfunction, mood disorders, and elevated risk of substance misuse — compound the original pain problem rather than resolving it.
The second is opioid-induced hyperalgesia, a paradoxical and clinically important phenomenon in which long-term opioid use produces increased sensitivity to pain rather than decreased sensitivity. The nervous system becomes amplified in its response to normal pain signals, patients report worsening pain even as doses are raised, and the pain itself becomes diffuse, poorly localized, and increasingly difficult to manage through any mechanism. The biological substrate involves excitation of NMDA receptors, increased spinal dynorphin expression, and disruption of descending pain inhibitory pathways. The clinical result is a vicious cycle in which more opioids produce more pain, which drives demand for more opioids — a cycle that is difficult to interrupt and that leaves patients in a worse functional state than they would have been without opioid therapy. Lee et al. in Pain Physician characterized opioid-induced hyperalgesia as a recognized and serious clinical phenomenon that may worsen pain with prolonged opioid therapy — and that recognition should be a standard part of the informed consent conversation before any patient is started on long-term opioid management.
The scale of harm extending beyond the individual patient is staggering. Approximately 80,000 of the 105,000 drug overdose deaths in the United States in 2023 involved opioids, and the number of opioid overdose deaths in 2023 was nearly ten times the number recorded in 1999. Globally, of approximately 600,000 deaths attributed to drug use each year, around 450,000 are due to opioid use. The additional individual risks — physical dependence and addiction even at therapeutic doses, suppression of sex hormones with long-term use, sedation-related falls and fractures particularly in older adults, and well-documented gastrointestinal effects — represent a harm profile that in the chronic musculoskeletal pain context is rarely justified by the modest and transient benefit opioids typically produce.
WHAT WORKS INSTEAD
Patient-Centered Alternatives to Opioid Therapy
The alternatives to opioid therapy for chronic musculoskeletal pain are not consolation prizes — they are, for most patients, more effective and more durable. Structured physical therapy and progressive exercise produce improvements in pain and function that are comparable to or superior to opioid therapy for most chronic musculoskeletal conditions, without the adverse effect profile and with benefits that compound over time rather than diminishing. Cognitive behavioral therapy addresses the central sensitization and psychological amplification that contribute substantially to the chronic pain experience and that pharmacological management alone cannot reach. Non-opioid pharmacological options including NSAIDs, duloxetine, and gabapentinoids offer meaningful relief for specific pain phenotypes with substantially lower risk profiles. Osteopathic manipulative medicine provides hands-on tools for addressing musculoskeletal dysfunction and improving mobility in patients for whom manual therapy is appropriate. Interventional procedures — nerve blocks, image-guided injections, radiofrequency ablation, and minimally invasive spine interventions — address confirmed pain generators directly and can produce durable relief that eliminates or substantially reduces the analgesic requirement. Regenerative medicine with PRP and BMAC offers the possibility of tissue-level improvement for tendon, joint, and disc pathology that is driving the pain rather than masking it.
The key in all of these approaches is what is missing from opioid prescribing as it has typically been practiced: a confirmed diagnosis, a treatment matched to that diagnosis, and a plan built around function rather than symptom suppression.
FOR REFERRING CLINICIANS
Patients on long-term opioid therapy for chronic musculoskeletal pain who have not had a comprehensive interventional spine or musculoskeletal evaluation represent one of the most important referral opportunities. Many of these patients have a treatable pain generator that has never been identified — and identifying it changes what is possible for their management. I offer comprehensive diagnostic evaluation including targeted image-guided diagnostic blocks to confirm pain sources, a full range of interventional procedures matched to confirmed diagnoses, non-opioid pharmacological optimization, and coordination of physical therapy and cognitive behavioral therapy as components of a comprehensive management plan. For patients seeking to discontinue opioid therapy, a structured transition plan built around confirmed diagnosis and matched non-opioid treatment is the most reliable pathway to success. I welcome direct physician-to-physician consultation.
PERSPECTIVE
A Note on Honest Conversations About Opioids
One of the most important things I can do for a patient on long-term opioid therapy for musculoskeletal pain is to tell them the truth — that the medication they have been taking for years is unlikely to be providing meaningful benefit at this stage, that the harms it carries are real and progressive, and that there are alternatives worth pursuing that have never been adequately offered to them. I do not prescribe opioids for chronic musculoskeletal or orthopedic conditions, and I make that clear to every patient from the first visit. That boundary exists because the evidence demands it — not because I am indifferent to their pain, but because I take their pain seriously enough to offer them something that actually works. That conversation is not always comfortable, and it requires time, care, and a genuine relationship of trust. But it is the conversation that changes trajectories. The chronic pain epidemic in this country was not created by patient weakness or physician malice — it was created by a system that reached for the most available tool without asking whether it was the right one. Correcting that requires physicians who are willing to do the harder diagnostic work, offer the more precise interventional options, and have the honest conversation about what opioids do and do not accomplish in the long run. That is the standard I hold myself to, and it is what every patient living with chronic musculoskeletal pain deserves.
DISCLOSURE & REFERENCES
This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Upadhyay J et al. 2010 (brain alterations in opioid dependence, J Neurosci); Lee M et al. 2011 (opioid-induced hyperalgesia, Pain Physician); Chou R et al. 2015 (long-term opioid therapy risks, Ann Intern Med); Vowles KE et al. 2015 (opioid misuse rates in chronic pain, Pain); Dowell D et al. 2022 (CDC opioid prescribing guidelines, MMWR); CDC Overdose Prevention Data 2024; WHO Guidelines on Opioid Dependence 2026.
ABOUT THE AUTHOR
Dr. Mahajer is a double board-certified Spine Physiatrist and Sports Medicine physician, fellowship-trained in Interventional Pain and Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine, the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), and holds medical licenses in Florida, New York, and California. He has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.
